Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous dendritic cell therapy (PT. Prodia Stem Cell Indonesia)
- Development stage
- Phase 2
- Lead developer
- Prodia Stem Cell Indonesia
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies
- Administration
- Intramuscular
01
Overview
This investigational autologous dendritic cell-based immunotherapy is being developed by PT. Prodia Stem Cell Indonesia (ProSTEM) for the treatment of advanced nasopharyngeal cancer. The therapy is designed as an adjuvant treatment for patients who have achieved a partial response or stable disease following standard chemoradiation. The process involves harvesting a patient's own monocytes, which are then differentiated into dendritic cells ex vivo and re-administered to the patient. These dendritic cells act as professional antigen-presenting cells, activating the patient's T-cell mediated immune response to target and eliminate residual tumor cells. In clinical trials, this therapy is often evaluated in combination with allogeneic dendritic cell secretomes to enhance immune activation in patients with low immunity post-chemoradiation.
- Other names
- Autologous Dendritic Cell as Adjuvant Therapyautologous dendritic cell-PT. Prodia Stem Cell Indonesia-nasopharyngeal cancer
02
Targets
γδ TCR (T-cell receptor)
Beyond the preview
Go deeper on autologous dendritic cell therapy (PT. Prodia Stem Cell Indonesia).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous dendritic cell therapy (PT. Prodia Stem Cell Indonesia).